ACTRN12614000877684尚未招募未知
In a pilot study looking at men with intermediate or high risk prostate cancer, we wish to investigate the incremental management impact of staging with NaF PET/CT compared to bone scintigraphy
Dr. Simon Harley0 个研究点目标入组 20 人开始时间: 2014年8月19日最近更新:
适应症
试验速览
- 阶段
- 未知
- 状态
- 尚未招募
- 发起方
- 入组人数
- 20
研究概览
简要总结
暂无简介。
研究设计
- 研究类型
- Interventional
- 分配方式
- Non-randomised trial
- 主要目的
- Diagnosis
- 盲法
- Open (masking not used)
入排标准
- 年龄范围
- 18 Years 至 100 Years（—）
- 性别
- Male
入选标准
- •All men aged 18 years and above with newly diagnosed, untreated biopsy confirmed prostate cancer with
- •intermediate to high risk prostate cancer as defined by D’Amico Classification (Gleason score equal to/greater than 7 , PSA greater/equal to 10)
排除标准
- •Men with a second (non-prostate) cancer
- •Men who have had previous neo-adjuvant hormonal or radiation therapy for prostate cancer.
- •Men unable to give informed consent
研究者
相似试验
已完成
1 期
A phase I study to determine the tolerability and safety of transdermally delivered oxycodone in combination with the novel penetration enhancer tocopheryl phosphate mix (TPM).To promote pain relief in healthy volunteers.Anaesthesiology - Pain managementACTRN12609000836235Phosphagenics Limited44
进行中（未招募）
不适用
A Prospective, Observational Study of Men With Premature Ejaculation Who Are Treated With PRILIGY™ or Alternate Care - PAUSEpremature ejaculationMedDRA version: 12.0Level: PTClassification code 10036596Term: Premature ejaculationEUCTR2009-011309-18-FIJanssen-Cilag International NV, Turnhoutseweg 30, 2340 Beerse, Belgium12,000
已完成
不适用
Oxidative stress markers and insulin pump therapyType 1 diabetesISRCTN12081042niversity of the Highlands and Islands (UK)48
进行中（未招募）
3 期
Randomised phase 3 trial of enzalutamide in first line androgen deprivation therapy for metastatic prostate cancer: ENZAMETProstate CancerACTRN12614000110684HMRC Clinical Trials Centre (CTC), University of Sydney1,125
进行中（未招募）
3 期
Randomised phase 3 trial of enzalutamide in androgen deprivation therapy with radiation therapy for high risk, clinically localised, prostate cancerCancer - ProstateProstate CancerACTRN12614000126617HMRC Clinical Trials Centre (CTC) , University of Sydney802